Need for Early Recognition of Amyloidosis in Cases of Unexplained Heart Failure: A Case Report

被引:0
作者
Kalluri, Sneha [1 ]
Abbasi, Jamil [2 ]
机构
[1] Baylor Scott & White All St Med Ctr, Internal Med, Ft Worth, TX 76104 USA
[2] Baylor Scott & White All St Med Ctr, Crit Care, Ft Worth, TX USA
关键词
intensive care unit; immunoglobulin; autoimmune disease; plasma cell dyscrasias; critical care; heart failure; light chain amyloidosis; liver dysfunction; cardiogenic shock; amyloidosis (al); DIAGNOSIS;
D O I
10.7759/cureus.40658
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Amyloidosis is a plasma cell dyscrasia that leads to the excessive production and deposition of mutant protein fragments in various organs. Cardiac amyloidosis is often implicated in two main subtypes: transthyretin (ATTR) and light chain (AL). While both subtypes increase the risk of restrictive cardiomyopathy, cardiogenic shock, and arrhythmias, poorer outcomes are seen in those with cardiac infiltration secondary to AL amyloidosis. Prognosis depends on the timing of diagnosis and the extent of the disease burden prior to recognition and treatment. The following case report describes a young patient who was admitted to the intensive care unit (ICU) for concerns of decompensated heart failure of unknown etiology, later determined to be due to amyloidosis. We describe her clinical course prior to and during hospital admission, along with the proposed physiologic factors that may have contributed to her poor outcome.
引用
收藏
页数:5
相关论文
共 19 条
  • [11] Light Chain (AL) Amyloidosis: The Journey to Diagnosis
    McCausland, Kristen L.
    White, Michelle K.
    Guthrie, Spencer D.
    Quock, Tiffany
    Finkel, Muriel
    Lousada, Isabelle
    Bayliss, Martha S.
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2018, 11 (02) : 207 - 216
  • [12] Melmed Gavin M, 2009, Proc (Bayl Univ Med Cent), V22, P280
  • [13] Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement
    Oubari, Sara
    Naser, Eyad
    Papathanasiou, Maria
    Luedike, Peter
    Hagenacker, Tim
    Thimm, Andreas
    Rischpler, Christoph
    Kessler, Lukas
    Kimmich, Christoph
    Hegenbart, Ute
    Schoenland, Stefan
    Rassaf, Tienush
    Reinhardt, Hans Christian
    Joeckel, Karl-Heinz
    Duerig, Jan
    Duehrsen, Ulrich
    Carpinteiro, Alexander
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (04) : 449 - 457
  • [14] Catastrophic Cardiac Amyloidosis
    Panduranga, Prashanth
    Mukhaini, Mohammed
    [J]. CARDIOLOGY RESEARCH AND PRACTICE, 2011, 2011
  • [15] Light-chain (AL) amyloidosis: Diagnosis and treatment
    Sanchorawala, Vaishali
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06): : 1331 - 1341
  • [16] Sidana Surbhi, 2018, Oncotarget, V9, P35607, DOI 10.18632/oncotarget.26289
  • [17] Approach to a patient with cardiac amyloidosis
    Strouse, Christopher
    Briasoulis, Alexandros
    Fonseca, Rafael
    Jethava, Yogesh
    [J]. JOURNAL OF GERIATRIC CARDIOLOGY, 2019, 16 (07) : 567 - 574
  • [18] AL Amyloidosis for Cardiologists Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review
    Wechalekar, Ashutosh D.
    Fontana, Marianna
    Quarta, C. Cristina
    Liedtke, Michaela
    [J]. JACC: CARDIOONCOLOGY, 2022, 4 (04): : 427 - 441
  • [19] Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications
    Xu, Linchun
    Su, Yongzhong
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)